» Articles » PMID: 36701047

FLCN-Driven Functional Adrenal Cortical Carcinoma with High Mitotic Tumor Grade: Extending the Endocrine Manifestations of Birt-Hogg-Dubé Syndrome

Overview
Journal Endocr Pathol
Specialties Endocrinology
Pathology
Date 2023 Jan 26
PMID 36701047
Authors
Affiliations
Soon will be listed here.
Abstract

Adrenal cortical carcinoma is an aggressive and rare malignancy of steroidogenic cells of the adrenal gland. Most adult adrenal cortical carcinomas are sporadic, but a small fraction may be associated with inherited tumor syndromes, such as Li-Fraumeni, multiple endocrine neoplasia 1, Lynch syndrome, and Beckwith-Wiedemann syndrome, as well as isolated case reports of non-syndromic manifestations occurring in the context of other pathogenic germline variants. Birt-Hogg-Dubé (BHD) is a rare autosomal dominant syndrome caused by germline pathogenic variants in the FLCN gene. BHD syndrome causes a constellation of symptoms, including cutaneous manifestations, pulmonary cysts and pneumothorax, and risk of renal tumors. With the exception of a single case of adrenal cortical carcinoma, very few reports on the occurrence of adrenal cortical neoplasia in patients with BHD syndrome have been described. However, information on variant allele fraction in the tumor was not available in the index case, which precludes any mechanism supporting loss of heterozygosity. Here we present a case of an adult-onset adrenal cortical carcinoma in a 50-year-old female, found to harbor a germline likely pathogenic variant in the FLCN gene, denoted as c.694C > T (p.Gln232Ter). Genetic testing on the tumor revealed the same FLCN variant at an allele fraction of 83%, suggesting a contributory role to the pathogenesis of the adrenal cortical carcinoma. This case further supports the expansion of the clinical presentation and tumor spectrum of BHD syndrome and the need to consider germline FLCN testing in the clinical genetic workup of patients with adrenal cortical carcinomas.

Citing Articles

Clinical integration of germline findings from a tumor testing precision medicine program.

Sanabria-Salas M, Anggala N, Gillies B, Farncombe K, Hofstedter R, Peck L BMC Cancer. 2025; 25(1):176.

PMID: 39885482 PMC: 11783960. DOI: 10.1186/s12885-025-13487-4.


Progress in Adrenal Cortical Neoplasms: From Predictive Histomorphology to FLCN-Driven Germline Pathogenesis and the Prognostic Performance of Multiparameter Scoring Systems in Pediatric Adrenal Cortical Neoplasms.

Mete O, Juhlin C Endocr Pathol. 2023; 34(2):176-178.

PMID: 37219723 DOI: 10.1007/s12022-023-09776-y.


New Perspective on the Genetic Dissection Underlying the Development of Parathyroid Cancer.

Falchetti A J Clin Endocrinol Metab. 2023; 108(12):e1751-e1752.

PMID: 37149780 PMC: 10655506. DOI: 10.1210/clinem/dgad253.

References
1.
Sharma E, Dahal S, Sharma P, Bhandari A, Gupta V, Amgai B . The Characteristics and Trends in Adrenocortical Carcinoma: A United States Population Based Study. J Clin Med Res. 2018; 10(8):636-640. PMC: 6031252. DOI: 10.14740/jocmr3503w. View

2.
Else T, Kim A, Sabolch A, Raymond V, Kandathil A, Caoili E . Adrenocortical carcinoma. Endocr Rev. 2014; 35(2):282-326. PMC: 3963263. DOI: 10.1210/er.2013-1029. View

3.
Else T . Association of adrenocortical carcinoma with familial cancer susceptibility syndromes. Mol Cell Endocrinol. 2012; 351(1):66-70. PMC: 3307589. DOI: 10.1016/j.mce.2011.12.008. View

4.
Else T, Lerario A, Everett J, Haymon L, Wham D, Mullane M . Adrenocortical carcinoma and succinate dehydrogenase gene mutations: an observational case series. Eur J Endocrinol. 2017; 177(5):439-444. DOI: 10.1530/EJE-17-0358. View

5.
Juhlin C, Bertherat J, Giordano T, Hammer G, Sasano H, Mete O . What Did We Learn from the Molecular Biology of Adrenal Cortical Neoplasia? From Histopathology to Translational Genomics. Endocr Pathol. 2021; 32(1):102-133. DOI: 10.1007/s12022-021-09667-0. View